➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
McKesson
Baxter
Merck

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

LATISSE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Latisse, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Allergan and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-five patent family members in eleven countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

US ANDA Litigation and Generic Entry Outlook for Latisse

A generic version of LATISSE was approved as bimatoprost by APOTEX INC on December 1st, 2014.

  Start Trial

Drug patent expirations by year for LATISSE
Drug Prices for LATISSE

See drug prices for LATISSE

Recent Clinical Trials for LATISSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 0
Tulane UniversityPhase 0
AllerganPhase 3

See all LATISSE clinical trials

Pharmacology for LATISSE
Paragraph IV (Patent) Challenges for LATISSE
Tradename Dosage Ingredient NDA Submissiondate
LATISSE SOLUTION/DROPS;TOPICAL bimatoprost 022369 2010-05-03

US Patents and Regulatory Information for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LATISSE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 SPC023/2002 Ireland   Start Trial SPC023/2002: 20040929, EXPIRES: 20170307
0660716 C300099 Netherlands   Start Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716 SPC/GB02/035 United Kingdom   Start Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 90957 Luxembourg   Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
McKesson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.